Prostacyclin pathway drugs

Prostacyclin pathway drugs are medicines that act like prostacyclin, a natural substance, or that act on its receptor. MeSH describes epoprostenol (prostacyclin) as a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation, and notes that its sodium salt has been used to treat primary pulmonary hypertension. The US label of Uptravi (selexipag) calls it a prostacyclin receptor agonist, and the US label of Remodulin (treprostinil) calls it a prostacyclin mimetic, each indicated for pulmonary arterial hypertension. This is the class page.

Also called Prostacyclin · Prostacyclin Receptor Agonist · Prostacyclin Receptor Agonists · Prostacyclin mimetic · Prostacycline Vasodilator

  • Drug
  • In this atlas

Overview

Technical summary

Class page. MeSH has no descriptor for the class; the nearest is D011464 (Epoprostenol, lastUpdated 2018-03-01), a drug descriptor whose entry terms include Prostacyclin, so it is a broad match. Its scope note describes a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. RxClass lists the established pharmacologic class on US drug labels Prostacyclin Receptor Agonist for selexipag and, spelled Prostacycline Vasodilator, for treprostinil and epoprostenol (read 2026-11-18); the aliases keep those spellings. The labels read are Uptravi (NDA207947, NDA214275; effective 2026-05-28) and Remodulin (NDA021272; effective 2026-07-02). RxClass gives these medicines two different established pharmacologic class names, so the class page groups them by label wording. No trial result, dose or instruction is recorded.

Drugs in this class

2 drugs in this atlas are filed under Prostacyclin pathway drugs, with the registry trials and FDA regulatory decisions this atlas holds for each. With Prostacyclin pathway drugs itself, the class has 0 distinct trials and 0 distinct FDA decisions; a trial or decision that two of them share counts once there.

About this drug

Level
Class
Mechanism
MeSH describes prostacyclin as a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation; the Uptravi label says selexipag is a prostacyclin receptor agonist that is structurally distinct from prostacyclin.

Classification codes

  • MeSH id.nlm.nih.gov linked data, retrieved 2026-11-18 D011464 Epoprostenol

Claims and evidence

No claims are published for this drug yet.

Record details

Record id
cardio:prostacyclin-pathway-drugs
Content hash
e14aebe12d533e167818f037bbc9c36c7ed5607d8b621b181246d602d72ce3b0